A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

NCT07032272 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Autoimmune and Chronic Inflammatory Diseases

Interventions

DRUG: remibrutinib

Sponsor

Novartis Pharmaceuticals